Group 1 - The core viewpoint emphasizes that China's pharmaceutical innovation industry is entering an unprecedented golden development period, driven by the "Healthy China" strategy and the focus on "new quality productivity" [1][2] - The government has highlighted the importance of "innovative drugs" in its work report, indicating strong policy support for the pharmaceutical sector, which is expected to drive economic transformation and enhance national competitiveness [2][3] - In 2024, the total amount of licensing-out agreements in China's innovative drug sector is projected to exceed $55 billion, showcasing the rapid growth and increasing global significance of Chinese innovative drugs [2][3] Group 2 - The private equity investment platform, Kunyuan Asset, is strategically positioned to capture opportunities arising from the "Healthy China" initiative, focusing on continuous innovation and deep research in pharmaceutical companies [3][5] - There is a significant market potential in China's innovative drug sector, with the market size being 30 times smaller than that of the U.S., indicating a vast opportunity for growth and investment [3][5] - The CRO (Contract Research Organization) market in China is expected to expand as the innovative drug industry rises, with a focus on companies that possess technological and platform advantages [7][11] Group 3 - Kunyuan Asset organized a visit to the leading pharmaceutical R&D service provider, Sunshine Nuohe, to enhance investor understanding of the CRO industry's investment logic and foster deeper integration between capital and industry [1][4] - During the visit, representatives learned about Sunshine Nuohe's unique strategy of "R&D services + pipeline cultivation + new quality industrial chain," which highlights the company's robust capabilities in drug development [6][7] - Sunshine Nuohe has over 430 R&D projects, with significant advancements in peptide therapies, showcasing its strong market value and innovation capabilities [7][10] Group 4 - The visit aimed to bridge the gap between investors and high-quality assets, facilitating a deeper understanding of the innovative medical sector from macro insights to micro validations [5][10] - Kunyuan Asset is committed to creating a value platform that empowers investors through continuous education and high-quality activities, enhancing their understanding of the pharmaceutical industry [11] - The aging population and the ongoing implementation of the "Healthy China" strategy are expected to usher in a golden era for the pharmaceutical and health industry, aligning with Kunyuan Asset's mission to support investors in navigating this landscape [11]